MPN Cancer Connection

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2...

PharmaEssentia taps Incyte alum Eric Vogel as it eyes Besremi expansion

PharmaEssentia taps Incyte alum Eric Vogel as it eyes Besremi expansion PharmaEssentia has hired Eric Vogel as its new U.S. Head of Commercialization, as it seeks to broaden the label of its rare blood cancer drug, Besremi, to a much wider market. | PharmaEssentia has hired Eric Vogel as its new U.S. Head of Commercialization as it seeks to broaden the label of its rare...

MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms

MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms - Leukemia Pharmacologic targeting of murine double minute 2 (MDM2) represents one of the most compelling strategies for therapeutic reactivation of wild-type p53 in hematologic malignancies. The MDM2–p53 autoregulatory loop is a central regulator of cellular stress responses, and in myeloid neoplasms—incl...

🔬 New Hope in the Fight Against Aggressive Blood Cancers

​A recent study published in Bone Marrow Transplantation provides a vital update on treating blast-phase myeloproliferative neoplasms (MPN-BP). While this condition is traditionally highly aggressive, new data shows that allogeneic stem cell transplantation is offering a curative path for approximately one-third of patients.

https://www.nature.com/articles/s41409-026-02842-z